The rockefeller university

Most drug discovery projects do not begin with a screening assay.

Instead, they begin with a research assay developed to answer a biological question. Investigators may already have an ELISA, enzyme assay, Western blot, immunoprecipitation assay, fluorescence assay, or cell-based assay that demonstrates an important biological interaction. These methods establish the underlying biology but are often not suitable for screening hundreds of thousands of compounds or for rapidly evaluating structure-activity relationships during medicinal chemistry optimization.

One of the principal roles of the Fisher Drug Discovery Resource Center is to translate these research assays into robust, automated, miniaturized, and cost-effective screening assays while preserving the underlying biology.

The Translation Process

Developing a screening assay rarely involves inventing a completely new assay. More often, it involves adapting an existing experimental system into a format compatible with automation, miniaturization, and large-scale screening.

Typical assay development includes:

• Evaluating existing research assays
• Selecting an appropriate detection technology
• Choosing suitable capture reagents and affinity tags
• Optimizing reagent concentrations and assay conditions
• Miniaturizing the assay to 384-well formats
• Validating assay robustness (Z′ factor, signal window, reproducibility)
• Reducing reagent costs for large screening campaigns
• Designing orthogonal confirmation assays

Throughout this process, the biological question remains the same. The experimental implementation evolves to meet the requirements of high-throughput screening.

Choosing a Detection Technology

Numerous complementary detection technologies are available for measuring biomolecular interactions in high-throughput screening. The appropriate choice depends upon the biology being studied, reagent availability, assay geometry, throughput requirements, and downstream validation strategy. These same technologies can also be adapted to quantify analytes in cell lysates, including second messengers, phosphoproteins, cytokines, and other biomarkers.

AlphaScreen® and AlphaLISA®

Alpha technologies are homogeneous, bead-based proximity assays that provide exceptional sensitivity and are particularly well suited for detecting protein-protein interactions and other biomolecular interactions involving relatively large molecular assemblies. Their approximately 200 nm effective detection distance provides flexibility when capture reagents or large proteins separate the interacting partners.

Like many modern assay platforms, AlphaScreen and AlphaLISA are highly modular. Donor and acceptor beads may be coupled through a variety of affinity reagents—including antibodies, streptavidin-biotin, GST, FLAG, His-tags, Fc domains, and other capture strategies—allowing the same detection chemistry to be adapted to many different biological systems.

Because donor beads are photosensitive, AlphaScreen assays should be assembled and incubated under subdued laboratory lighting. Careful optimization is also required to minimize singlet oxygen quenching and avoid the high-dose “hook effect” that can occur at very high analyte concentrations.

TR-FRET

Time-resolved fluorescence resonance energy transfer (TR-FRET) uses lanthanide donors and fluorescent acceptors to generate highly reproducible ratiometric measurements. Commercial implementations include HTRF®, LANCE®, and LanthaScreen™, each based on the same underlying TR-FRET principle while employing different donor and acceptor chemistries.

Because TR-FRET relies on energy transfer over distances of only a few nanometers, labeling strategy and molecular geometry become important considerations during assay development. The availability of both europium- and terbium-based donors also allows multiplexed assay formats in appropriate applications.

ELISA

Although ELISA requires wash steps and is generally less suitable for very large screening campaigns, it remains one of the most valuable starting points for assay development. Many biological targets already have validated antibody pairs, commercial assay kits, and extensive published protocols, allowing investigators to establish assays rapidly before adapting them for high-throughput screening.

In many projects, ELISA serves as the starting point for assay development. Existing antibodies, commercial kits, and published protocols often provide a rapid path toward establishing proof-of-concept experiments before adapting the biology to a homogeneous AlphaScreen or TR-FRET format suitable for high-throughput screening.

When ELISA represents the most appropriate solution, the DDRC supports automated 384-well ELISA workflows using our BioTek EL406 microplate washer/dispenser integrated with BioStack plate stackers.

Assays Are Modular

One of the most important concepts in assay development is modularity.

Most binding assays consist of three largely independent components:

• The biology — the interaction being measured.
• The capture strategy — antibodies, affinity tags, streptavidin-biotin, His-tags, GST, FLAG, Fc domains, and other reagents used to recognize or immobilize the interacting molecules.
• The detection chemistry — AlphaScreen®, AlphaLISA®, TR-FRET, ELISA, fluorescence polarization, luminescence, or another reporting technology.

One of the most powerful aspects of modern assay development is that these modules are largely independent. The biological interaction remains unchanged, while the capture strategy and detection chemistry can often be exchanged or optimized without altering the underlying biology. This flexibility allows investigators to adapt existing research assays into formats better suited for automation, miniaturization, or orthogonal validation.

Miniaturization and Cost Matter

Assay performance is only one consideration during screening.

Commercial research kits are frequently designed for experiments involving dozens or hundreds of samples. Screening campaigns may require hundreds of thousands of assay wells.

At this scale, reagent cost becomes a major consideration. An assay costing more than one dollar per well rapidly becomes prohibitively expensive when screening hundreds of thousands of compounds.

Assay development therefore includes careful optimization of reagent concentrations, reaction volumes, plate formats, and reagent sourcing to reduce cost while maintaining assay quality and reproducibility. In many cases, replacing commercial kits with individually sourced antibodies, affinity reagents, and detection components substantially reduces screening costs while preserving assay performance.

Screening Is Only the Beginning

Primary screening identifies candidate compounds—not validated drug leads. Every active compound represents a hypothesis that must be tested through independent experimental approaches.

Successful discovery programs incorporate orthogonal confirmation assays, concentration-response studies, biophysical characterization, selectivity testing, and mechanistic experiments to distinguish genuine biological activity from assay-specific artifacts.

For this reason, assay development should always be considered within the context of the complete screening cascade rather than as an isolated experiment.

DDRC Perspective

The Fisher Drug Discovery Resource Center does not advocate a single assay technology.

Instead, we work with investigators to determine which combination of biology, capture strategy, detection technology, automation, and validation provides the most reliable answer to the scientific question being addressed.

Our objective is not simply to build screening assays. It is to translate biological questions into robust experimental systems that generate reliable evidence for therapeutic discovery. Whether a project begins with a published ELISA, an enzyme assay, a cell-based assay, or a novel biological observation, our goal is to develop an assay that is scientifically rigorous, economically practical, and capable of supporting modern drug discovery.